Company Encyclopedia
View More
name
Biogen
BIIB.US
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
1.946 T
BIIB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking56/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.31%B
    • Profit Margin15.98%A
    • Gross Margin79.93%A
  • Growth ScoreC
    • Revenue YoY4.77%C
    • Net Profit YoY-0.41%C
    • Total Assets YoY3.16%C
    • Net Assets YoY11.30%B
  • Cash ScoreC
    • Cash Flow Margin625.79%C
    • OCF YoY4.77%C
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreB
    • Gearing Ratio37.66%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares

    Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2

    TradingView·
    US
    BIIB
    +0.68%
    TradingView·
    US
    BIIB
    +0.68%

    Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors?

    Biogen and Eisai presented new LEQEMBI data at the CTAD conference, highlighting long-term benefits in Alzheimer's progression and a new subcutaneous formulation. This could enhance Biogen's investment narrative by potentially improving treatment uptake. However, challenges remain with Alzheimer's uptake, reimbursement, and competition. Biogen's collaboration with Dayra Therapeutics aims to diversify its pipeline. Despite LEQEMBI's promising data, investors should consider pricing and reimbursement pressures on specialty drugs. Biogen's projected revenue is $9.4 billion by 2028, with varied community valuations reflecting differing expectations.

    Simplywall·
    US
    BIIB
    +0.68%
    Simplywall·
    US
    BIIB
    +0.68%

    Eisai Co., Ltd. and Biogen Inc. Present New Data

    Eisai Co., Ltd. and Biogen Inc. presented new data at the 18th CTAD Conference on lecanemab, a monoclonal antibody for Alzheimer's treatment. Findings suggest early and long-term use of lecanemab slows disease progression, with significant time savings in progression from MCI to mild and moderate AD. The subcutaneous formulation shows similar efficacy and safety to intravenous dosing. Eisai leads global development and regulatory submissions, co-commercializing with Biogen.

    marketscreener·
    US
    BIIB
    +0.68%
    marketscreener·
    US
    BIIB
    +0.68%

    18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

    Eisai and Biogen presented new data at the CTAD Conference 2025 on the benefits of LEQEMBI (lecanemab-irmb) for early Alzheimer's treatment. Long-term use may delay disease progression by up to 8.3 years in certain patients. A subcutaneous formulation for LEQEMBI, under review in the U.S., shows similar efficacy and safety to intravenous dosing. The findings suggest early and continued treatment with LEQEMBI can significantly slow Alzheimer's progression and maintain cognitive function.

    prnewswire·
    US
    BIIB
    +0.68%
    prnewswire·
    US
    BIIB
    +0.68%

    BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs

    Biogen (BIIB) is advancing its immunology pipeline with felzartamab showing strong efficacy in late AMR and potential for durable disease control in IgA nephropathy and PMN. The company also has multiple phase 3 and proof-of-concept studies underway, and its lupus programs are progressing with differentiated mechanisms and endpoints. This information is based on an AI-generated summary of Biogen's Piper Sandler 37th Annual Healthcare Conference Audio Transcript from December 3, 2025.

    TradingView·
    US
    BIIB
    +0.68%
    TradingView·
    US
    BIIB
    +0.68%
    © 2025 Longbridge｜Disclaimer